Immunogenic composition

Patent metadata

Field	Value
Publication number	US-11241495-B2
Application number	US-201816179476-A
Country	US
Kind code	B2
Filing date	Nov 2, 2018
Priority date	Jun 27, 2005
Publication date	Feb 8, 2022
Grant date	Feb 8, 2022

Abstract

The present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.

First claim

The invention claimed is:

1. A method of immunizing a human host against disease caused by Neisseria meningitidis infection, comprising administering to the host an immunoprotective dose of an immunogenic composition comprising: a stabilizing agent; and lyophilized N. meningitidis capsular polysaccharides from serogroups A, C, W, and Y, wherein:
the serogroup A capsular polysaccharide has an average size of 300 kDa;
the serogroup C capsular polysaccharide has an average size of 200 kDa;
the serogroup Y capsular polysaccharide has an average size of 101-300 kDa;
the serogroup W capsular polysaccharide has an average size of 101-300 kDa; and
wherein each N. meningitidis capsular polysaccharide is a N. meningitidis capsular polysaccharide conjugate comprising a N. meningitidis capsular polysaccharide conjugated to a tetanus toxoid carrier protein,
wherein the immunogenic composition elicits in the host an immune response which comprises an antibody titer against MenA, MenC, MenW, and Men Y greater than 0.3 μg/ml.

2. The method of claim 1 , wherein the serogroup Y capsular polysaccharide has an average size of 190-300 kDa; and the serogroup W capsular polysaccharide has an average size of 190-300 kDa.

3. The method of claim 1 , wherein the stabilizing agent comprises sucrose.

4. The method of claim 1 , wherein the stabilizing agent comprises trehalose.

5. The method of claim 1 , wherein the human is aged up to 14 months.

Assignees

• Glaxosmithkline Biologicals Sa

Inventors

• Biemans Ralph Leon
• Boutriau Dominique
• Capiau Carine
• Denoel Philippe
• Duvivier Pierre
• Poolman Jan

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K39/292

  Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen · CPC title

• A61P11/04

  for throat disorders · CPC title

• A61K39/0018

  Combination vaccines based on acellular diphtheria-tetanus-pertussis · CPC title

• A61K39/116

  Polyvalent bacterial antigens · CPC title